The Best Way to Beat Cancer is to Catch it Early.

AS SIMPLE AS A SINGLE BLOOD TEST

Cancer Differentiation Analysis (CDA) Technology

Anpac Bio

LEADING BIO-MEDICAL SCIENCE INNOVATION

Anpac Bio-Medical Science Co., Ltd. is led by award winning and internationally respected biomedical and nanotechnology scientists, medical professionals, and engineering experts -- creating and launching break-through, leading-edge, early cancer screening, detection, and diagnostic technology.

Anpac is unique among cancer research and treatment companies -- incorporating a novel, cross-disciplinary combination of medicine, bio-chemistry, chemistry, materials, fluid mechanics, signal detection and processing, physics, precision machine engineering, and software engineering – to achieve vastly superior early cancer screening and detection technology.

Anpac's "Cancer Differentiation Analysis" (CDA) Proprietary Technology

Published earlier this year as "game changing", in the Nobel Prize Laureate Summit on Biomedical Science (NPLS) documentation, research indicates Anpac's "Cancer Differentiation Analysis" (CDA) medical devices effectively reinvent early cancer screening and detection.

By analyzing simple, in vitro, whole, "Blood Biopsies", and applying Anpac's proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac's CDA technology identifies cancer and other disease with measurably-greater sensitivity, specificity, and accuracy, than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer "false positives"; and at a cost substantially lower than traditional testing (such as imaging).

Comprehensive research validity data from over 30,000 cases indicate Anpac's CDA diagnostics far exceed existing or competing technologies - revealing a sensitivity and specificity rate range of 75%-90% for over ten different types of cancer, with the ability of early stage detection for most of them.
Anpac's consistent Breast Cancer detection sensitivity and specificity rates of over 80% to date (versus standard/traditional early detection tests, generating an approximately 30% sensitivity/specificity rate).

Anpac Bio

Anpac Bio



What is CDA Technology?

FACT SHEET

Anpac Bio's patented Cancer Differentiation Analysis (CDA) Technology is a revolutionary breakthrough in early cancer detection. It identifi es early signals of threatening cancer—often before the threat grows into tumors.

With a simple whole blood test, CDA diagnostics identify over 10 different cancers earlier, more accurately, with greater sensitivity and specifi city, and without side effects in patients.

Comprehensive research validity data from more than 30,000 test cases confirm the results, which were called "game-changing" in 2015 Nobel Prize Laureate Summit on Biomedical Science publications.

How Anpac's CDA Technology is Different

- A simple whole blood test, analyzing whole "Blood Biopsies" allows CDA technology to identify cancer with far greater accuracy.
- CDA diagnostics can detect and identify early signals of threatening cancer—and the type of cancer, indicating where in the body it is located.
- CDA technology can differentiate between pre-cancer diseases and early stage cancer, providing valuable and timely cancer risk assessment.
- CDA's delivers sensitivity and specificity in the range of 75%–90% for over ten different types of cancer, with the ability of early stage detection for most of them, and fewer false positives.
- For example: CDA early stage breast cancer tests revealed the disease with 82% sensitivity and 87% specificity.
- CDA technology is multi-level and multi-parameter, vs. existing screening methods that analyze only one.

Advantages of CDA Technology:

Earlier Detection: Often detects threatening cancer at its earliest stages—saving lives.

Consistently More Accurate in sensitivity and specificity—with far fewer false positives.

Safe and Fast: Only 2 ml whole blood sample, with no side effects. Results reported within days.

Cost Effective: Far less expensive than traditional screening (such as imaging). And fewer false positives, reducing the need for costly biopsies.

Automated System: Sample is measured without pre-treatment, providing results immediately—directing medical professionals to threatening cancer cell location.

Real-Time Monitoring: Allows doctors to monitor, augment, or change cancer treatment "real time", without additional stress to patients.

10	30K+
CANCER TYPES	CONFIRMED TESTS

75% TO 90% ACCURACY RATE

Anpac CDA Technology is Game Changing.

Anpac CDA Technology Catches Cancer Early



Anpac Bio

Anpac CDA Technology is Game Changing.

Anpac Bio-Medical Leadership Team

Anpac Bio-Medical's scientists and leadership team have been invited to share the company's breakthrough CDA research results at respected, international health events such as the Nobel Prize Laureate Summit on Biomedical Science, the American Society of Cancer Oncology, the international Breast Cancer Symposium, and others. Anpac Bio-Medical Science Company's Leadership Team includes:

Dr. Chris Yu: Founder and Chief Executive Officer

Dr. Chris Yu, Founder and CEO of Anpac Bio-Medical Science, was born to a medical doctor's family. He attended medical school, before later changing his studies to Physics and earning his Ph. D. degree from Pennsylvania State University.

Dr. Yu is a highly successful business executive, innovative engineer, and pioneering inventor, filing over 200 patent applications (and earning over 100 to date). A proven, series entrepreneur, Dr. Yu has consistently delivered solid returns to investors (over 100X and 30x respectively in two start-up companies).

Over his 20-year career, Dr. Yu's innovative and profitable work has spanned the fields of medical devices for cancer screening, biology (bio-membranes), signal detection, transducer design and fabrications, reagents, IC materials, and integrated circuits, among many other technologies.

Dr. Yu's experience includes leadership in three Fortune 500 companies (including Motorola); before launching his own, successful start-up companies. For example, at one Fortune 500 Company, Dr. Yu was the inventive Research & Development Director that was instrumental in building a small division of a NYSE company, into a highly successful, technology company with more than $200 million in revenue, and a lucrative NSDAQ IPO. Throughout his career, innovative high-tech products created and developed by him, have achieved over $3 billion in revenue.

Dr. Yu's combined education background in medicine, Physics, and engineering, coupled with his extensive experience and delivery in both major corporations and his own, successful start-up companies, has earned him the respect of business leaders, government officials, and media worldwide. As such, Dr. Yu is frequently engaged to speak at professional conferences, entrepreneurship events, and educational organizations; and is committed to community relations and corporate social responsibility (which he models and supports throughout Anpac Bio-Medical).

Anpac Bio

Dr. Herbert Yu: Co-Founder & Chief Science Officer

Professor Herbert Yu, Co-Founder and Chief Scientist of Anpac Bio-Medical, is the latest in a long, family line of medical doctors. Dr. Herbert Yu earned his M.D. at medical school, before later earning a Ph. D. degree in Clinical Biochemistry from University of Toronto.

Over his 20-year career, Dr. Yu has been actively engaged in leading-edge, cancer research, that including breakthrough work in the areas of carcinogenic factors, molecular epidemiology, and others. Professor Yu served as an Assistant Professor, Associate Professor, and Full Professor at Yale University's School of Medicine, where much of the research leading to Anpac's CDA technology was conducted.

Currently, Dr. Yu is a Deputy Director at the Cancer Research Center of University of Hawaii. Professor Yu's recent research interests include new technologies and mechanisms for cancer diagnosis, and the studies of biomarkers for cancer diagnosis and prognosis. He has completed many clinical and epidemiologic studies on several major cancer sites, including the breast, ovary, liver, lung, endometrium, and prostate. He has also investigated DNA methylation in tumor suppressor and DNA repair genes, methylator phenotype in relation to tumor progression, methylation pattern in multiple promoters, methylation regulation of micro RNA, and physical activity and epigenetic regulation.

Ms. Drisha Leggitt: Vice President, Business Development

Drisha Leggitt is the Vice President of U.S. Business Development for Anpac Biomedical Science Company. In this role, Ms. Leggitt is responsible for partnership and investment development, communications and marketing strategic planning and execution, investment and external communications tool development/outreach, and managing Anpac Bio-medical Science Company's external affairs, advocacy, and brand awareness activities with regards to Anpac's "Cancer Differentiation Analysis" Technology (CDA) research and program.

Ms. Leggitt has a Bachelor's Degree in Communications; and a Master's Degree in Organizational Development from the University of San Francisco. She has earned over 100 professional awards to date, including being named, the Public Relations Society of America's inaugural, "Influencer of the Year," the Arts & Business Council's "Business Volunteer of the Year," named by PR News Magazine as one of only 60 inaugural, "Top Women in PR" Worldwide, and top honors from such organizations as the International Association of Business Communicators, the Points of Light Foundation, Council of State Governments, the international Association for Women in Communications, Rotary International, and many others.

A cancer survivor herself (in remission over 20 years to date), and recently, Leggitt is passionate about early detection technology and research, a proud member of the Anpac Bio-medical Science Company leadership team -- applying her public relations, marketing, development and related skills to better educate the public and potential Anpac partners, regarding the importance of Anpac's cutting-edge technology and research successes.

Anpac Bio

Anpac Employees

Anpac Bio-Medical employs over 60 dynamic, creative, innovative, self-motivated and successful scientists, researchers, engineers, sales, marketing, and business development experts, worldwide. Anpac's management and staff attended the world's top universities (such as Yale University), were recruited from Fortune 500, NYSE- and NASDAQ-listed corporations, and are recognized leaders in the medical device industry (with experience working in General Electric, Bayer, Roche, etc.).
Collectively and throughout their careers, Anpac's employees have filed over 300 patents, (with more than 200 have been issued to date) – and maintain a very strong "track record" of successfully navigating innovative ideas from the Research & Development stage, to laboratory trials, to Pilot Plant development, to full-scale manufacturing and market growth, to IPO success and global sales of over $3 billion dollars to date.

Anpac Bio-Medical U.S Headquarters & Services

In addition to Anpac's proprietary CDA medical devices, Anpac provides a multitude of disease screening and detection services, reagents, testing processing and services, data management, consulting services, and innovative health related training courses with focus in leading edge cancer diagnostics related products and services.

Anpac Bio-Medical U.S. is expanding its national services through its new, administration and research operations in California. Establishing joint venture and investment partnerships, expanding research and development, hiring and engaging top bioscience, technology, and engineering talent, filing multiple patents, and conducting national clinical trials from its California-base, Anpac Bio-Medical plans to triple its disease screening and product development within three years.

For Further Information

For further information regarding Anpac Bio-Medical Science Co., Ltd or its research results, please check: www.Anpacbio.com

Anpac Bio

Anpac in the news

Media organizations serving over 22 million people worldwide have published and/or reported on Anpac Bio-Medical Science Company.

Anpac in the news

Anpac Bio-Medical Science Co. has pledged $50,000 to the UC Davis Child Family Institute for Innovation and Entrepreneurship to underwrite student fellowships and support the annual Biomedical and Engineering Entrepreneurship Academy.

RELATED LINKS

Read the article

RELATED CONTENT



Anpac Bio

Anpac in the news



Home Mail Search News Sports Finance Celebrity Weather Answers Flickr Mobile More

YAHOO! FINANCE

Search Finance Search Web

Sign In Mail

Recent

Quotes you view appear here for quick access.

Quote Lookup Go

Finance Home
My Portfolio
My Quotes News
Market Data
Yahoo Originals
Business & Finance
Personal Finance
CNBC
Contributors

$6.95 Flat-rate online equity & ETF trades

E*TRADE Invest Now

Recommended Games

More games »

Compare Brokers

Anpac Bio Partnering with Asia's Largest Hospital & Other International Medical Institutions for Unprecedented 50,000 Individual Esophageal Cancer Screening

PRNewswire Anpac Bio-Medical Science Company April 7, 2016 7:05 PM

SACRAMENTO, April 7, 2016 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Co., Ltd. ("Anpac Bio"), announced today the company is partnering with Asia's largest medical institution, the *First Affiliated Hospital of Zhengzhou University (FAHZU)*, the prestigious *Fudan University (FU)*, and three other respected medical institutions, to launch the largest Esophageal Cancer (EC) investigation to date in the world. Using Anpac Bio's proprietary, "Cancer Differentiation Analysis" (CDA) technology, over 50,000 individuals – including those deemed "high risk" -- will be screened, in an effort to identify the disease at its earliest stages.

Anpac Bio

EC is the eighth-most common cancer globally, with 456,000 new cases annually. However, EC rates vary widely among countries, with about half of all cases occurring in China; greater than 70% of all newly diagnosed EC cases worldwide.

Early EC detection is particularly difficult for clinicians because the cancer does not have an easily discernable "Biomarker"; patients rarely seek treatment until after symptoms persist and the

What to read next

Options are picking up where credit default swaps left off

Ron Paul Issues Warning On Gold
Sponsored Stansberry Research

Why companies save money when female employees travel

FOX 14 The Right News. The Right Time.

NEWS AT 9:00

Mike Olmstead • Tim Spears • Doug Heady

Fox 14 for the Web APPS Sky Watch Weather Fox 14 on TV Sports Four-State Jobs Lifestyle

0

Anpac Bio-Medical Presenting 'Breakthrough' Cancer Screening Tech/Research At Breast Cancer Symposium * September 25-27, 2015

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Anpac Bio-Medical Science Company

Anpac CDA Breast Cancer Detection Over 80% Specificity & Sensitivity

SACRAMENTO, Calif., Sept. 16, 2015 /PRNewswire/ -- Anpac Bio-Medical Science Company Chief Executive Officer Dr. Chris Yu and Anpac scientists will be presenting "breakthrough," Breast Cancer screening and early detection research results at the upcoming "Breast Cancer Symposium" in San Francisco, California, September 25-27, 2015.

Reporting outcomes generated through Anpac's novel, non-invasive, "Cancer Differentiation Analysis" (CDA) technology, Anpac's team will share with Symposium attendees Anpac's consistent Breast Cancer detection sensitivity and specificity rates of over 80% to date (versus standard/traditional early detection tests, generating an approximately 30% sensitivity/specificity rate).

Published earlier this year as "game changing", by the Nobel Prize Laureate Summit on Biomedical Science (NPLS), research indicates Anpac's CDA medical devices effectively reinvent early Breast Cancer screening and detection. By analyzing simple, in vitro, whole, "Blood Biopsies", and applying Anpac's proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac's CDA technology identifies Breast Cancer with measurably-greater sensitivity, specificity, and accuracy, than most current, conventional Breast Cancer early screening methods. And it does so without *any* harmful side effects in patients; generating far fewer "false positives"; and at a cost substantially lower than traditional testing (such as imaging).

Of most importance to Symposium participants, Anpac's CDA technology can reveal threatening Breast Cancer cells, before they form into tumors – key to patient survival rates. According to Cancer Research U.K., more than 90% of women diagnosed with breast cancer at the earliest stage survive their disease for at least five years; compared to around 15% for women diagnosed with the most advanced stage of disease (http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/survival#heading-Three).

The scientific Abstract outlining Anpac's CDA Breast Cancer research samples/method, results, etc., will post September 25.

Anpac has gone through long-term rigorous research and clinical verification process to bear fruits in various aspects this year.

- Published numbers of influential paper at world's top academic conferences.
- Fully recognized by internationally renowned medical institutions and experts.
- Approved and granted with medical devices registration certificates by China Food and Drug Administration.

Following is the abstract of Anpac published papers in 2015 Breast Cancer Symposium in San Francisco.

Investigations of breast cancer screening using a novel in vitro diagnostics technology.

Sub-category:
General Screening
Category:
Risk Assessment, Prevention, Early Detection, and Screening
Meeting:
2015 Breast Cancer Symposium
Session Type and Session Title:
Poster Session A: Risk Assessment, Prevention, Early Detection, Screening, and Local/Regional Therapy
Abstract Number:
13
Poster Board Number:
Poster Session A Board #D5
Citation:
J Clin Oncol 33, 2015 (suppl 28S; abstr 13)
Author(s): Hongmei Tao, Xuedong Du, Xing Tang, Yue Lin, Da Lou, Chris Chang Yu; AnPac Bio-Medical Science and Technology Co., LTD, Shanghai, China; Anpac Bio-Medical Science Technology Co., Ltd., Shanghai, China; Anpac Bio-Medical Science Co Ltd, Shanghai, China

Methods: Blood samples from breast cancer group (n = 222), and control subjects (n = 204) were collected in EDTA tubes. CDA values were measured using a CDA medical device. The results were shown in Table 1 and Figure 1 below.

Results: The average CDA values of breast cancer and control groups were 50.43 and 34.03 (rel. units) respectively. The results indicated that breast cancer could be significantly distinguished from the control ($p < 0.001$). Area under ROC curve was 0.914. When Youden Index reached the maximum, sensitivity and specificity was 82.0% and 89.2% respectively.

Conclusions: Initial results showed that CDA technology could be a potential candidate for breast cancer screening.

Summary of CDA test results.

Group	Sample Size	Age Range	Age Mean	Age Median	CDA Mean (rel. units)	CDA Median (rel. units)	CDA STDEV
Control	204	30 - 84	60	60	34.03	34.81	7.65
Breast Cancer	222	23 - 79	53	54	50.84	50.43	9.69

For further information regarding Anpac Bio-Medical Science Co., Ltd. or its research results, please check: www.AnpacBio.com
Ms. Drisha Leggitt: Drisha_Leggitt@AnpacBio.com
Mr. Tao Cheng: Tao_Cheng@AnpacBio.com



01

EARLY DETECTION

The best way to beat cancer is to catch it early. Early detection and prompt treatment saves lives; decreases need for prolonged treatment and negative side effects; increases quantity of life, and significantly reduces healthcare costs. Effective and accurate screening is the key to early detection.

02

ACCURACY UNMATCHED

Anpac Bio's Cancer Differentiation Analysis"(CDA) technology effectively detects and identifies early signals of threatning cancer, and the type of cancer or location in the body, often in its earliest stages and before it grows into tumors.

03

INNOVATIVE & EFFECTIVE

Comprehensive research validity data from over 25,000 cases to date indicate Anpac Bio's CDA screening and diagnostics far exceed existing or competing disease screening technologies — revealing a sensitivity and specifity rate range of 75%-90% for over ten different types of cancer to data.

04

GAME CHANGING

Reported as, "Game Changing" in multiple, published reports, Anpac Bio's CDA technology reinvents early cancer detection. By analyzing simple, in vitro, whole, "Blood Biopsies", using Anpac Bio's proprietary, multi-level, multi-parameter, diagnostic algorithms, CDA identifies cancer with measurably-greater sensitivity, specificity, and accuracy, than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer "false positives"; and at a cost substantially lower than traditional testing.

The best way to beat cancer is to catch it early.

Anpac Bio's innovative CDA technology reinvents early-stage cancer detection.